Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bosutinib
Drug ID BADD_D00286
Description Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.
Indications and Usage Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
Marketing Status approved
ATC Code L01EA04
DrugBank ID DB06616
KEGG ID D03252
MeSH ID C471992
PubChem ID 5328940
TTD Drug ID D0OB0F
NDC Product Code 54893-0042; 54893-0041; 54893-0048; 63539-193; 63539-117
UNII 5018V4AEZ0
Synonyms bosutinib | SKI606 | SKI-606
Chemical Information
Molecular Formula C26H29Cl2N5O3
CAS Registry Number 380843-75-4
SMILES CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory failure22.02.06.002; 14.01.04.003--
Retching07.01.07.0020.000437%Not Available
Salivary gland enlargement07.06.03.0020.000246%Not Available
Scab23.03.03.0040.000873%Not Available
Sciatica17.10.03.001; 15.10.01.0010.000627%Not Available
Second primary malignancy16.16.01.0140.002239%
Skin discolouration23.03.03.0050.001634%Not Available
Skin disorder23.03.03.0070.000929%Not Available
Skin exfoliation23.03.07.0030.000817%Not Available
Skin lesion23.03.03.0100.000627%Not Available
Sneezing22.12.03.0240.000437%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000795%Not Available
Spleen disorder01.09.02.0030.000302%Not Available
Splenomegaly01.09.02.0010.000112%Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.0140.000224%
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.001063%Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.0020.002160%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.0020.000246%Not Available
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.000112%
Ulcer08.03.06.0010.000492%Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.006--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine cancer21.07.02.003; 16.12.05.0010.000112%Not Available
Vein disorder24.03.02.0150.000381%Not Available
Viral upper respiratory tract infection22.07.02.004; 11.05.04.007--Not Available
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages